Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Multi-component Intervention for Diabetes in Adults With Serious Mental Illness (MIDAS)

15. september 2021 opdateret af: Dilip V. Jeste, University of California, San Diego

Multi-component Intervention for Diabetes in Adults With Serious Mental Illness (MIDAS)

Persons with schizophrenia and other serious mental illnesses have a high risk for type 2 diabetes and an increased risk of premature mortality compared to the general population. The goals of the proposed study are to implement a multimodal lifestyle intervention to reduce that risk in these individuals living in residential care facilities, a common housing modality for people with serious mental illnesses. If successful, this intervention will lead to reduction in excess medical comorbidity and mortality in persons with serious mental illnesses.

Studieoversigt

Detaljeret beskrivelse

Serious mental illnesses (SMI), including schizophrenia, bipolar disorder, and schizoaffective disorder, are associated with increased medical comorbidity and premature mortality from diabetes and cardiovascular disease. Unhealthy lifestyles, including energy-dense (obesogenic) diet, sedentary behavior, and cigarette smoking are important risk factors for diabetes and accelerated biological aging. All of these risk factors are potentially modifiable. There is considerable literature documenting the effectiveness of strategies to prevent and manage diabetes in the general population; yet, these interventions are rarely offered to people with SMI. Residential Care Facilities (RCFs), called Board-and-Care Homes in California, are a common housing modality for patients with SMI; they provide a venue that can maximize efficiency and sustainability of a lifestyle intervention. The goals of the proposed four-year study are to tailor a multi-component intervention to this high-risk group. The study will be a hybrid effectiveness-implementation (Hybrid Type 1) trial of a Multi-component Intervention for Diabetes risk reduction in Adults with SMI (MIDAS) in licensed RCFs in San Diego county. As a Hybrid Type 1 study, the primary emphasis will be on determining the effectiveness of the intervention to achieve desired health outcomes while also systematically collecting data on its implementation within RCFs that will inform implementation strategy refinement. Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction. The investigators will employ a modified cluster-randomized stepped wedge and adaptive trial design involving 210 residents with SMI and 120 staff members from 12 RCFs. The RCFs will be divided randomly into four cohorts of three RCFs each. Each cohort will be tested over a 15-month period that includes three phases: a three-month initial control phase (no intervention, from baseline month 0 to end of month 3), a six-month intervention phase (months 4 through 9), and a six-month follow-up phase (no intervention, months 10 through 15). All the study participants will be assessed quarterly during the 15-month period. Our investigators will train RCF staff (especially the Activity Director and cook) to increase physical activity and reduce smoking, and to implement healthful dietary modifications among the residents, using evidence-based interventions. During the intervention phase, the RCF Activity Director will conduct twice-weekly manualized group sessions on education about diabetes, nutrition, exercise, and smoking cessation/reduction, to deliver a multi-component group intervention. We will also explore if there are improvements in blood-based research biomarkers of insulin resistance and inflammation in the RCF residents with SMI. This project is responsive to RFA-MH-17-608, and related to NIMH Strategic Objective #3.3B: testing interventions for effectiveness in community practice settings. If successful, MIDAS will be sustained and disseminated, and would lead to reduction in excess medical comorbidity and mortality associated with SMI.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

210

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Dilip V Jeste, MD
  • Telefonnummer: (858) 534-4020
  • E-mail: djeste@ucsd.edu

Undersøgelse Kontakt Backup

  • Navn: Danielle K Glorioso, LCSW
  • Telefonnummer: (858) 246-0767
  • E-mail: dglorioso@ucsd.edu

Studiesteder

    • California
      • La Jolla, California, Forenede Stater, 92093
        • Rekruttering
        • University of California, San Diego Division of Geriatric Psychiatry
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Dilip V Jeste, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Participants: A total of 12 RCFs (30 to 45 beds each), 210 resident participants, and 120 staff members (1 manager, 2 activity directors, 1 cook, and 6 other staff members per facility) will be enrolled.

Inclusion and Exclusion Criteria:

Residential Care Facilities (RCFs):

Inclusion Criteria:

  1. Licensed by California Division of Social Services' Community Care Licensing
  2. Serves only individuals with SMI
  3. Has >15 residents currently living in the facility
  4. Willing to participate

Staff Participants:

Inclusion Criteria:

  1. Age >21 years
  2. Fluent in English
  3. Written informed consent to participate

Exclusion Criteria:

(1) Plans to leave the RCF during the next year.

Resident Participants:

Inclusion Criteria:

  1. Age 18 - 65 years
  2. Chart diagnosis of an SMI, mainly schizophrenia, schizoaffective disorder, or bipolar disorder
  3. Current treatment with antipsychotics
  4. Fluent in English
  5. Written informed consent to participate in this study

Exclusion Criteria:

  1. Chart diagnosis of dementia or intellectual disability disorder
  2. Active substance abuse (non-tobacco)
  3. Medical problems that interfere with ability to complete assessments and intervention

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Control Phase
3-month initial control phase (no intervention, month 1-3)
Eksperimentel: Intervention Phase
6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Body Mass Index (BMI in kg/m^2)
Tidsramme: Baseline to 9 months and sustained at 15 months
Change in Body Mass Index
Baseline to 9 months and sustained at 15 months
Waist Circumference
Tidsramme: Baseline to 9 months and sustained at 15 months
Change in Waist Circumference
Baseline to 9 months and sustained at 15 months
Fasting Glucose
Tidsramme: Baseline to 9 months and sustained at 15 months
Change in Fasting Glucose
Baseline to 9 months and sustained at 15 months
Hemoglobin A1c or HbA1c
Tidsramme: Baseline to 9 months and sustained at 15 months
Change in Hemoglobin A1c or HbA1c
Baseline to 9 months and sustained at 15 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Diet/Nutrition - Plasma Carotenoid Levels
Tidsramme: Baseline to 9 months and sustained at 15 months
Plasma Carotenoid levels reflect changing dietary vegetable and fruit intake.Nutrition Data Systems for REsearch (NDS-R) Protocol
Baseline to 9 months and sustained at 15 months
Diet/Nutrition - Serum Lipid Levels
Tidsramme: Baseline to 9 months and sustained at 15 months
Plasma Carotenoid levels reflect changing dietary vegetable and fruit intake.
Baseline to 9 months and sustained at 15 months
Objective Measure of Physical Activity
Tidsramme: Baseline to 9 months and sustained at 15 months
For 7 days during each assessment period, participants will wear the GT3X+ Actigraph, which measures movement and intensity of activity, and has good validation with VO2max. It provides estimates of activity by seconds, that can be categorized into minutes spent in sedentary, light, moderate, and vigorous activity using calibration thresholds.
Baseline to 9 months and sustained at 15 months
Smoking - Expired Breath Carbon Monoxide (CO) Levels
Tidsramme: Baseline to 9 months and sustained at 15 months
Change in Smoking - Objective Measure of Cigarette Use: Expired Breath Carbon Monoxide (CO) level (parts per million) is measured with a handheld device. CO monitoring is used primarily as a check on recent smoking, though it has also been used to indicate reductions in smoking.
Baseline to 9 months and sustained at 15 months
Smoking - Change in Smoking through Recall
Tidsramme: Baseline to 9 months and sustained at 15 months
Change in Smoking - Quantity and frequency of cigarette use for the prior week using a timeline followback procedure. Smoking reduction calculated by % change in average cigarettes/day across assessments.
Baseline to 9 months and sustained at 15 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

28. december 2018

Primær færdiggørelse (Forventet)

31. maj 2022

Studieafslutning (Forventet)

31. maj 2022

Datoer for studieregistrering

Først indsendt

5. juli 2018

Først indsendt, der opfyldte QC-kriterier

9. august 2018

Først opslået (Faktiske)

13. august 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. september 2021

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. september 2021

Sidst verificeret

1. september 2021

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

3
Abonner